Navigation Links
Data from Patient Subsets of e-HEALING, a Worldwide Registry, Support Use of OrbusNeich's Genous(TM) Bio-Engineered R Stent(TM) as Alternative to Drug- Eluting Stents
Date:9/3/2007

Report of Positive Results with Innovative Pro-Healing Stent is Featured at

ESC Congress 2007

VIENNA, Austria, Sept. 3 /PRNewswire/ -- OrbusNeich today announced that post-marketing data from patient subsets of a global registry support the use of the company's Genous(TM) Bio-engineered R stent(TM) as an alternative to drug-eluting stents.

Presented today by Robbert de Winter, M.D., Ph.D., at the European Society of Cardiology (ESC) Congress 2007 in Vienna, Austria, the data from OrbusNeich's e-HEALING registry show:

* For 296 diabetic patients at six months, the target lesion

revascularization (TLR) rate was 2%, which is much lower than was

anticipated

* A TLR rate of 1.9% for 213 chronic total occlusion (CTO) patients at ]

six months

* For 923 patients with statin use, the major adverse cardiac events

(MACE) rate at six months was 5.7%, while 116 patients without statin

use experienced a MACE rate of 6.9% over the same period

"This real-world data strengthen our belief that Genous is a very promising alternative to drug-eluting stents," said de Winter, a co-principal investigator of the study and director of the catheterization laboratory at the Academic Medical Center in Amsterdam. "Genous appears to have the same efficacy as drug-eluting stents but a better safety profile with only minimal dual-antiplatelet therapy requirements. This is an important finding in that physicians are becoming reluctant to burden their patients with the cost and compliance issues associated with drug-eluting stents and their extensive dual-antiplatelet therapy requirements."

OrbusNeich's e-HEALING is a multi-center, worldwide (outside the United States) prospective registry of patients treated with the Genous Bio- engineered R stent in accordance with the instructions for use. The protocol recommends that patients receive two weeks of statin treatment prior to the procedure and one month of clopidogrel treatment after the procedure. Clinical follow-up takes place at 30 days, six months and 12 months. The primary outcome of the registry is target vessel failure at 12 months.

Unlike drug-eluting stents, Genous, which is coated with an antibody, captures a patient's endothelial progenitor cells (EPCs) to accelerate the natural healing process. EPCs circulate in the bloodstream and are involved in the repair of blood vessels. When attracted to the surface of Genous, EPCs rapidly form an endothelial layer over the stent that provides protection against thrombus and minimizes restenosis.

OrbusNeich designs, develops, manufactures and markets innovative medical devices for the treatment of vascular diseases. The company's product portfolio includes the Genous(TM) Bio-engineered R stent(TM), an antibody- coated device that is the first-ever stent to capture a patient's endothelial progenitor cells (EPCs) to accelerate the natural healing process following placement. Other products are stents, balloons and guiding catheters marketed under the names of Blazer(TM), R stent(TM), Sapphire(TM), Avita(TM), Avita HP(TM), SafeCut(TM), Lumina(TM) and Saffron.

A global company, OrbusNeich is headquartered in Hong Kong and has operations in Fort Lauderdale, Fla.; Hoevelaken, The Netherlands; and Shenzhen, China. OrbusNeich, which has provided cardiology devices to physicians through its predecessor companies since 1979, today supplies products in more than 60 countries. For more information, visit http://www.OrbusNeich.com.


'/>"/>
SOURCE OrbusNeich
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. One in Three Heart Attack Patients Have No Chest Pains
2. Amphetamines Help Recovery of Stroke Patients
3. Painkillers Do Not Shorten Dying Patients Lives
4. Patients With Filariasis More Prone To HIV Infection
5. Glivec - New Hope For CMC Patients
6. Patient’s perception of health status helps in better recover
7. HIV infected patients can travel safely abroad
8. New vaccine helps allergy and asthma patients
9. Doctors operate upon patients in candlelight- latest from the quake scene
10. New vaccine helps allergy and asthma patients
11. Are cancer patients being taken for a ride?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2020)... ... June 25, 2020 , ... Pivot Point Consulting, ... IT Services Firm, expanded its telehealth services to provide end-to-end solutions ... expert and a Consulting Magazine “2020 Women Leaders in Technology” award winner, ...
(Date:6/24/2020)... ... June 24, 2020 , ... ... today announced that Wexford Physician Hospital Organization (PHO) has successfully deployed SPH’s Population ... within the framework of value-based care. Use of Population Care is benefitting more ...
(Date:6/23/2020)... ... 2020 , ... Anesthesia Progress —Receiving dental care during ... virus, which is primarily found in oral, nasal, and pharyngeal mucosa and in ... or by aerosols produced during aerosol-generating procedures (AGPs). Given the transmission type, four ...
(Date:6/23/2020)... (PRWEB) , ... June 22, 2020 , ... A June ... a face mask. In light of the country slowly opening back up while adjusting ... available products for areas of the face that aren’t covered such as eyelids, lashes, ...
(Date:6/23/2020)... ... June 22, 2020 , ... A May 27 ... an individual’s risk for oral cancer and periodontitis, also known as gum disease. Pasadena-based ... users of more old fashioned tobacco products -- should quit but not everyone will, ...
Breaking Medicine News(10 mins):
(Date:6/25/2020)... ... June 25, 2020 , ... ... International Research Congress (IRC) , which is being conducted entirely online for the ... premier global platform for the discussion and dissemination of state-of-the-art research on facioscapulohumeral ...
(Date:6/24/2020)... LAUDERHILL, Fla. (PRWEB) , ... June 24, 2020 ... ... the answers to a number of common questions on County Line Chiropractic’s ... answer common health questions. , County Line Chiropractic has six locations in the ...
(Date:6/23/2020)... ... June 23, 2020 , ... One size fits all ... working to prove a similar, universal program does not work as an overall response ... affected nearly everyone’s daily life in one way or another, from plummeting stock markets ...
Breaking Medicine Technology: